HealthMedical Research
Experimental Pill Doubles Survival in Pancreatic Cancer
New oral drug daraxonrasib nearly doubled survival in metastatic pancreatic cancer patients, marking a breakthrough against one of the deadliest cancers.
—5 min read
Tag
2 articles
New oral drug daraxonrasib nearly doubled survival in metastatic pancreatic cancer patients, marking a breakthrough against one of the deadliest cancers.
A new experimental pill nearly doubles survival for advanced pancreatic cancer patients, targeting the long-undruggable KRAS mutation.